Download PDF
Thromb Haemost 1967; 17(03/04): 578-584
DOI: 10.1055/s-0038-1654182
Originalarbeiten - Original Articles - Travaux Originaux
Schattauer GmbH

The Clot-Promoting Effect of Adenosine-5’-Diphosphate (ADP). II. Site of Action[*]

J Pizzuto   **
1   Department of Medicine, University of Utah College of Medicine, Salt Lake City, Utah, U.S.A.
,
P Didisheim   ***
1   Department of Medicine, University of Utah College of Medicine, Salt Lake City, Utah, U.S.A.
,
Th. C Bithell
1   Department of Medicine, University of Utah College of Medicine, Salt Lake City, Utah, U.S.A.
› Author Affiliations
Further Information

Publication History

Publication Date:
26 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

1. ADP accelerates the rate of the “contact” phase of thromboplastin generation by a mechanism which is independent of its known effects on platelets.

2. The acceleratory effect is the result of an interaction between ADP and a plasma factor which is not clearly identifiable with any generally recognized coagulation factor (i. e., factors I-XIII).

* This investigation was supported by a research grant (AM-04489) and a graduate training grant (AM-5098) from the National Institutes of Arthritis and Metabolic Diseases, National Institutes of Health, Bethesda, Maryland.


** Present address : Departamento de Hematologia, Hospital General, Centro Médico Nacional. Av. Cuauhtemoc N° 330, México 7, D. F. (Mexico).


*** Present address : Section of Clinical Pathology, Mayo Clinic, Rochester, Minnesota.


 

  • References

  • 1 Hellem A. J. The adhesiveness of human blood platelets in vitro. Thesis. Scand. J. clin. Lab. Invest. 12 51 1960
    PubMedSearch in Google Scholar
  • 2 Silver M. D, Stehbens W. E. Platelet reaction to adenosine diphosphate in vivo. Nature (Lond.) 205: 91 1965;
    CrossrefPubMedSearch in Google Scholar
  • 3 Gaarder A, Jonsen J, Laland S, Hellem A. J, Owren P. A. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature (Lond.) 192: 531 1961;
    CrossrefPubMedSearch in Google Scholar
  • 4 Owren P. A. Physiopathologie du temps de saignement. Nouv. Rev. franç. Hémat 3: 280 1963;
    PubMedSearch in Google Scholar
  • 5 Owren P. A. Nutrition and thrombosing atherosclerosis. Nutr. et Dieta (Basel) 6: 156 1964;
    PubMedSearch in Google Scholar
  • 6 Odegaard A. E, Skalhegg B. A, Hellem A. J. Increased activity of “Anti-Willebrand Factor” in diabetic plasma. Thrombos. Diathes. haemorrh. (Stuttg.) 11: 27 1964;
    PubMedSearch in Google Scholar
  • 7 Clayton S, Cross M. J. The aggregation of blood platelets by catecholamines and by thrombin. J. Physiol. (Lond.) 169: 82 1963;
    PubMedSearch in Google Scholar
  • 8 Caen J, Michel H. L’Activité agregante du sérum. (Plasma déñbriné par la thrombine). Rev. franç. Étud. clin. biol 9: 1001 1964;
    PubMedSearch in Google Scholar
  • 9 Caen J, Michel H. Agrégation des plaquettes à L’ADP. (Acide adenosine diphosphorique). Rev. franç. Étud. clin. biol 9: 999 1964;
    PubMedSearch in Google Scholar
  • 10 Nordoy A, Chandler A. B. The influence of dietary fats on the adenosine diphosphate induced platelet thrombosis in the rat. Scand. J. Haemat 1: 202 1964;
    PubMedSearch in Google Scholar
  • 11 Hellem A. J, Owren P. A. The mechanism of the hemostatic function of blood platelets. Acta haemat. (Basel) 31: 230 1964;
    CrossrefPubMedSearch in Google Scholar
  • 12 Born G. V. R, Gross M. J. The aggregation of blood platelets. J. Physiol. (Lond.) 168: 178 1963;
    CrossrefPubMedSearch in Google Scholar
  • 13 Mustard J. F, Hegardt B, Rowsell H. G, MacMillan R. L. Effect of adenosine nucleotides on platelet aggregation and clotting time. J. Lab. clin. Med 64: 548 1964;
    PubMedSearch in Google Scholar
  • 14 Pizzuto J, Giorgio A. J, Didisheim P. The clot-promoting effect of adenosine-5’-diphosphate (ADP). I. Mechanism of action. Thrombos. Diathes. haemorrh. (Stuttg.) 15: 428 1966;
    PubMedSearch in Google Scholar
  • 15 O’Brien J. R. Some effects on blood coagulation of erythrocytes and other cells. J. clin. Path 22: 45 1959;
    PubMedSearch in Google Scholar
  • 16 Margolis J. Glass surface and blood coagulation. Nature (Lond.) 178: 805 1956;
    PubMedSearch in Google Scholar
  • 17 Ratnoff O. D, Grunt J. D. Activation of Hageman factor by solutions of ellagic acid. J. Lab. clin. Med 03: 359 1964;
    PubMedSearch in Google Scholar
  • 18 Breckenridge R. T, Ratnoff O. D. The role of proaccelerin in human blood coagulation. Evidence that proaccelerin is converted to a prothrombin-converting principle by activated Stuart factor : with notes on the anticoagulant action of soybean trypsin inhibitor, protamine sulfate, and hexadimethrine bromide. J. clin. Invest 44: 302 1965;
    CrossrefPubMedSearch in Google Scholar
  • 19 Biggs R, MacFarlane R. G. Human Blood Coagulation. 3rd ed.. F. A. Davis Company; Philadelphia: 1962
    Search in Google Scholar
  • 20 Nossei H. L. The Contact Phase of Blood Coagulation. F. A. Davis Company; Philadelphia: Blackwell Scientific Publications 1964
    Search in Google Scholar
  • 21 Didisheim P, Mibashan R. S. Activation of Hageman factor (factor XII) by long-chain saturated fatty acids. Thrombos. Diathes. haemorrh. (Stuttg.) 9: 346 1963;
    PubMedSearch in Google Scholar
  • 22 Haanen G, Schoenmakers J. G. G. One-stage assay for Hageman factor (factor XII). Further studies on the role of Hageman factor in blood coagulation. Thrombos. Diathes. haemorrh. (Stuttg.) 9: 557 1963;
    PubMedSearch in Google Scholar
  • 23 Waaler B. A. Contact activation in the intrinsic blood clotting system. Scand. J. clin. Lab. Invest. 11 37 1959
    PubMedSearch in Google Scholar
  • 24 Schiffman S. S, Rapaport S. I, Ware A. S, Mihl J. W. Separation of plasma thromboplastin antecedent (PTA) and Hageman factor (HF) from human plasma. Proc. Soc. exp. Biol. (N. Y.) 105: 453 1960;
    CrossrefPubMedSearch in Google Scholar
  • 25 Pascuzzi C. A, Spittel Jr. J. A, Thompson Jr. J. H, Owen Jr. G. A. Thromboplastin generation accelerator, a newly recognized component of the blood coagulation mechanism present in excess in certain thrombotic states. J. clin. Invest 40: 1006 1961;
    CrossrefPubMedSearch in Google Scholar
  • 26 Hathaway W. E, Belhasen L. D, Hathaway H. S. Evidence for a new plasma thromboplastin factor. I. Case report, coagulation studies and physico-chemical properties. Blood 26: 621 1965;
    PubMedSearch in Google Scholar
  • 27 Nilsson I. M, Blombäck M, Jorpes E, Blombäck B, Johansson S. von Willebrand disease and its correction with human plasma fraction I—0. Acta med. scand 159: 179 1957;
    PubMedSearch in Google Scholar
  • 28 Didisheim P, Hattori K, Lewis J. H. Hematologic and coagulation studies in various animal species. J. Lab. clin. Med 53: 866 1959;
    PubMedSearch in Google Scholar
  • 29 Marcus A. J, Zucker M. D. The Physiology of Blood Platelets. Grune & Stratton; New York and London: 1965
    Search in Google Scholar
  • 30 Soulier J. P. A new adsorption agent for coagulant factors. J. clin. Path 12: 303 1959;
    CrossrefPubMedSearch in Google Scholar